This stock is not for the timid. Buy when no one is and Sell when everyone's buying. This stock has to reach a point of equilibrium and base a few days. It's been gradually selling off from $1.70's to .455 to .023 and has had several nice bounces into the .07's. Institutions and large shareholders have taken a beating on paper. It would be prudent for them to average down but then again, who knows what their particular set of circumstances is?
I believe INNMF has more dry powder left and once this heads back through .06 it will be chased once again.
They have nearly $6,000,000 in cash reserves and the clinical study has not been halted. We'll be getting updates within the next month and volume will re-enter.
Right now INNMF's experiencing an oversold base building event similar to a blood tranfusion. Old shareholders that just cant take the pain any longer, have thrown in the towel and new investors are picking up the pieces.
I've been actively trading the shares and am now building a position for the next leg sideways to up.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM